結核分枝桿菌檢測市場:市場規模（按細分市場）、份額、監管、報銷、預測（~2033）

結核病有兩種感染方式:潛伏性結核病和活動性結核病。 在潛伏性結核病中，結核桿菌在體內保持休眠狀態。 儘管大多數人沒有表現出症狀，但這些患者被認為有發生活動性結核感染的風險。 結核病可以透過多種檢查來檢測，包括結核皮膚試驗（TST）、幹擾素Gamma釋放測定（IGRA）血液檢查、核酸擴增檢驗（NAAT）、痰液塗片鏡檢和培養。 此外，胸部 X 光檢查通常用於診斷結核感染。 多重抗藥性結核病對全球結核病根除工作構成日益嚴重的威脅。 由於檢測基礎設施不一致以及實驗室專家和臨床醫生的短缺，診斷很困難。 多重抗藥性結核病被定義為至少對異煙□和利福平抗藥性的結核分枝桿菌，而廣泛抗藥性結核病被定義為對更多藥物抗藥性，包括氟奎諾酮類藥物以及三種注射（阿米卡星、卡那黴素、捲曲黴素）中的任何一種。

結核分枝桿菌診斷測試包括 IGRA 測試和結核分枝桿菌 NAAT 測試。

本報告深入了解全球結核分枝桿菌檢測市場，提供競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。

目錄

結核病檢測試劑市場現況及競爭狀況

• 對主要產業趨勢的見解
• 2015 年至 2033 年結核分枝桿菌檢測按細分市場劃分的市場總收入和市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• 結核病檢測市場的SWOT分析
• 結核分枝桿菌檢測市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Mycobacterium Tuberculosis Tests market for the year 2020 and beyond. The tuberculosis (TB) infection has two modes of existence, latent TB and active TB. For latent TB, the mycobacterium is dormant within the body. The majority of individuals do not exhibit symptoms, but these patients are considered to be at risk for developing an active TB infection. Tuberculosis can be detected by a number of different tests including the tuberculosis skin test (TST), blood tests of interferon gamma release assays (IGRA), nucleic acid amplification tests (NAATs), sputum smear microscopy tests, and culture tests. Additionally, chest x-Rays are also often used to help diagnose TB infection. Multidrug-resistant tuberculosis is an increasingly serious threat to the eradication of global TB. Hard to diagnose due to the inconsistent testing infrastructure and lack of laboratory specialists and clinicians. MDR-TB is defined as the TB bacilli being resistant to at least isoniazid and rifampicin, while XDR-TB is resistant to more medicaments including fluoroquinolone, and to one of the three injectable drugs (amikacin, kanamycin, and capreomycin).

The Mycobacterium Tuberculosis diagnostic tests include IGRA and Mycobacterium Tuberculosis NAAT tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Mycobacterium Tuberculosis Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Mycobacterium Tuberculosis Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Mycobacterium Tuberculosis Tests market.
• Competitive dynamics insights and trends provided for Mycobacterium Tuberculosis Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Qiagen NV, Oxford Immunotec Ltd, Danaher Corp, Molbio Diagnostics Pvt Ltd, Hologic Inc, F. Hoffmann-La Roche Ltd, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Mycobacterium Tuberculosis Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Mycobacterium Tuberculosis Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Mycobacterium Tuberculosis Tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Mycobacterium Tuberculosis Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Mycobacterium Tuberculosis Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable